Stocktoria
Tvardi Therapeutics, Inc. TVRD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-01-31
Tvardi Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $7.1M | $21.0M | $41.9M | $23.0M |
| R&D expense | $18.0M | $23.6M | $108.5M | $91.9M | $82.7M |
| Operating income | -$26.7M | -$28.1M | -$121.5M | -$87.5M | -$89.1M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$18.2M | -$29.4M | -$118.5M | -$85.5M | -$88.4M |
| EPS (diluted) | $-3.26 | $-11.42 | $-26.26 | $-19.12 | $-1.74 |
| Operating cash flow | -$23.5M | -$18.3M | -$92.1M | -$78.7M | -$60.1M |
| Free cash flow | — | -$19.4M | -$94.5M | -$78.8M | -$60.1M |
| Cash & equivalents | $20.7M | $31.6M | $51.8M | $63.7M | $13.5M |
| Inventory | — | $900,000 | $2.8M | $2.4M | $2.6M |
| Total assets | $32.1M | $35.2M | $125.8M | $182.2M | $247.1M |
| Total liabilities | $11.1M | $40.8M | $68.8M | $23.5M | — |
| Shareholders' equity | $20.9M | -$91.1M | -$62.1M | $158.8M | $227.5M |
Source: SEC EDGAR filings · CIK 0001346830 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.